Last reviewed · How we verify

ACYCLOVIR SODIUM

FDA-approved approved Small molecule Quality 35/100

Acyclovir Sodium is a marketed antiviral drug primarily indicated for treating Herpes Simplex in immunocompromised patients. Its key strength lies in its established use and efficacy in this patient population, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.

At a glance

Generic nameACYCLOVIR SODIUM
ModalitySmall molecule
PhaseFDA-approved
First approval1982

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: